Investor Contacts: | |
Richard T. Schumacher, President & CEO | Pressure BioSciences, Inc. |
Edward H. Myles, Sr. Vice President of Finance & CFO | (508) 580-1818 (T) |
·
|
expansion
of the Company’s direct US sales force from one to five full-time domestic
sales directors by mid-year 2007
|
·
|
expansion
of the Company’s international distributor network in anticipation of the
expected launch of its PCT product line outside of the US in early
2008
|
·
|
the
Company’s submission of a purchase order to Source Scientific LLC -
effective Monday, March 26, 2007 - for 20 Barocycler NEP3229 instruments;
these units are in addition to the 25 units ordered in 2006, the
last 20
of which are expected to be received by the Company over the next
three
months; the Company will place all 40 of these instruments into inventory
when received, where they will remain until sold to customers or
used by
collaborators
|
·
|
the
Company’s submission of a purchase order to Source Scientific LLC -
effective Monday, March 26, 2007 - for nine uniquely-designed, portable
Barocycler instruments (NEP2320) to be used by the Company’s sales force
as lightweight, demonstration units for the
NEP3229
|
·
|
the
exhibition of the Company’s PCT product line at a number of
national/international conferences, including the 2007 Cambridge
Healthtech Institute’s GOT Summit - Proteomic Sample Preparation
Conference in Boston, MA from April 10-13, 2007, a meeting at which
the
Company’s Vice President of Research and Development, Dr. Alexander
Lazarev, will deliver a presentation on the use of PCT in the preparation
of samples for proteomic analysis; the 2007 BIO International Meeting
in
Boston, MA from May 6-9, 2007; and the 2007 American Diabetes Association
(ADA) Meeting in Chicago, Il from June,
22-26
|
·
|
efforts
over the past 10 months that have resulted in a significant reduction
in
weight, improvement in operating performance, and reduction in overall
manufacturing costs of the Barocycler NEP3229 - these advantages
will be
incorporated in all 40 units expected to be available for sale in
2007
|
·
|
the
receipt of approximately $450,000 from the sale of 101,000 shares
of
Panacos Pharmaceuticals common stock since March 13,
2007
|
·
|
the
announcement in early March 2007 of our second NIH Phase I SBIR grant
award in the past six months
|
·
|
the
continued addition of collaborators who are recognized experts in
many
areas of the life sciences, including sub-cellular complexes,
anti-bioterrorism, cancer, and
agriculture
|